136 patents
Page 4 of 7
Utility
RepublicationRIP1 Inhibitory Compounds and Methods for Making and Using the Same
5 Aug 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Esteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Filed: 16 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
15 Jul 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
Filed: 23 Mar 21
Utility
Amide Compounds and Method for Making and Using
15 Jul 21
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 24 Feb 21
Utility
Kinase inhibitors and methods for making and using
13 Jul 21
Vanessa Taylor, Yan Chen, Rose Yen
Filed: 12 Feb 20
Utility
Irak Inhibitors and Method for Making and Using
17 Jun 21
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 24 Feb 21
Utility
TGF-ß inhibitors
1 Jun 21
Marina Gelman, Pingyu Ding, Todd Kinsella, Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
Filed: 29 Mar 16
Utility
2,4-pyrimidinediamine compounds and their uses
18 May 21
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Filed: 19 Jun 19
Utility
Heterocyclic RIP1 Inhibitory Compounds
13 May 21
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 6 Nov 20
Utility
TGF-SS Inhibitors
6 May 21
Marina Gelman, Todd Kinsella, Somasekhar Bhamidipati, Ihab Darwish, Rajinder Singh, Jiaxin Yu
Filed: 2 Nov 20
Utility
RIP1 inhibitory compounds and methods for making and using the same
13 Apr 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Vanessa Taylor, Jiaxin Yu, Esteban Masuda, Ihab Darwish, Yan Chen
Filed: 2 May 19
Utility
Tyrosine Kinase Inhibitors
18 Mar 21
Ihab Darwish, Jiaxin Yu, Rao Kolluri, Sacha Holland
Filed: 25 Nov 20
Utility
Nrf2 Activating Compounds and Uses Thereof
18 Mar 21
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 20 Oct 20
Utility
Amide compounds and method for making and using
16 Mar 21
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors.
Kin Tso, Hui Li, Yan Chen, Rose Yen, Vanessa Taylor, Thilo Heckrodt, Rajinder Singh, Simon Shaw
Filed: 2 Aug 19
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP 1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Jiaxin Yu, Ihab Darwish, Vanessa Taylor, Rao Kolluri, Yan Chen, Simon Shaw, Somasekhar Bhamidipati, Zhushou Luo
Filed: 4 Sep 20
Utility
RIP1 Inhibitory Compounds and Methods for Making and Using the Same
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Yan Chen, Jiaxin Yu, Simon Shaw, Ihab Darwish, Vanessa Taylor, Somasekhar Bhamidipati, Zhushou Luo, Rao Kolluri
Filed: 4 Sep 20
Utility
Heterocyclic RIP1 Kinase Inhibitors
11 Mar 21
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds.
Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor
Filed: 4 Sep 20
Utility
IRAK inhibitors and method for making and using
9 Mar 21
Disclosed embodiments concern interleukin receptor associated kinases (IRAK) inhibitors, such as oxazole compounds, and compositions comprising such inhibitors.
Hui Li, Thilo Heckrodt, Yan Chen, Ryan Kelley, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung
Filed: 18 Jun 19
Utility
AMPK-activating heterocyclic compounds and methods for using the same
9 Mar 21
Dane Goff, Donald Payan, Rajinder Singh, Simon Shaw, David Carroll, Yasumichi Hitoshi
Filed: 25 Jun 19
Utility
Nrf2 activating compounds and uses thereof
9 Mar 21
Aspects of the present disclosure include compounds that activate Nrf2.
Matthew Duncton, Rajinder Singh
Filed: 2 Apr 20
Utility
Pyrazole Compounds, Formulations Thereof, and a Method for Using the Compounds And/or Formulations
4 Mar 21
Lu Chou, Matt Duan, Ihab Darwish, Simon Shaw, Somasekhar Bhamidipati, Vanessa Taylor, Yan Chen, Dazhong Fan, Zhushou Luo
Filed: 28 Aug 20